A recent advisory from the Drugs Consultative Committee (DCC) highlights the imperative for all states to provide comprehensive vaccine data on manufacturing and sales to the Central Drug Regulator.
Understanding WHO’s Global Benchmarking Tool (GBT)
The WHO’s GBT is the cornerstone for assessing and benchmarking a country’s regulatory functions concerning vaccines.
This tool serves as a prerequisite for the procurement of vaccines by UN agencies from Indian vaccine manufacturers.
The Central Drugs Standard Control Organisation (CDSCO) and associated institutions undergo assessments by WHO, ensuring adherence to international standards.
DCC’s Advisory: A Call to Action
CDSCO’s Checklist and SOP: Ensuring Quality Assurance
This move aims to establish common practices in the inspection process and create uniform inspection reports, aligning with global benchmarks.
States’ Role and Challenges
Despite the clear directive for states to furnish data, challenges persist.
However, the DCC stressed that data from all states is essential for both manufacturing and sales premises.
Importance of State Data Submission
The upcoming National Regulatory Agency (NRA) assessment necessitates comprehensive data from all states.
This includes information on human resources, Good Distribution Practices inspection reports of vaccine distributors, and uniform checklists for licensing premises of vaccine manufacturing and sales.
The need for a robust Risk-Based Sampling plan further underscores the importance of timely and accurate data submission.
CDSCO’s communication to States: A Collaborative Effort
The CDSCO has communicated all state/UT Drugs Controllers to provide detailed information promptly.
This includes a comprehensive database of technical staff, supporting the implementation of Good Regulatory Practices, Good Review Practices, and Quality Management Systems.
Standard Evaluation of Vaccines by WHO
WHO’s evaluation of vaccines encompasses a thorough review of the manufacturing process, compliance verification, sample lot testing, and site audits.
The Global Benchmarking Tool guides this process, emphasizing a standardized approach and reliance on responsible NRAs.
Role of NRAs in Regulatory Oversight
Collaborative agreements with WHO streamline the prequalification process, allowing reliance on NRA assessments, testing, and inspection reports.
WHO’s Recognition of Indian Regulatory Authority
The WHO’s recognition of the Indian regulatory authority in 2017 marked a significant achievement.
With a maturity level of four, the highest possible, and a level three in four functions, India’s regulatory system gained international acknowledgment for its effectiveness and improvement trends.
Maturity Levels: A Measure of Success
Maturity level four indicates sustained improvement trends, while level three reflects systematic improvements and data availability.
These levels, as defined by the Ministry of Health and Family Welfare, demonstrate India’s commitment to regulatory excellence.
Acknowledgment by Health Ministry and WHO
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: